🚨 New Analysis Alert: Our latest deep dive on $KHC is live on Substack.
We unpack the company’s storied history, the costly missteps post-merger, and the bold “Growth Architect” transformation underway.
Why KHC is a compelling value stock with growth optionality — offering a 7.2% yield while the market catches up.
Read the full institutional-grade analysis & investment thesis here: open.substack.com/pub/alphat…
202
Alpha Talon Investment Research Limited. retweeted
another way to look at past 2mos from goldman. biotech degrossing highest since '21.
Alpha Talon Investment Research Limited. retweeted
How it feels to ask the Chinese ai models for help on something Claude won’t agree to
Alpha Talon Investment Research Limited. retweeted
This is the JPM oil report everyone's talking about.
Alpha Talon Investment Research Limited. retweeted
FRANCE BACKS KNOT FOR ECB PRESIDENT
France would support former Dutch central-bank chief Klaas Knot to succeed Christine Lagarde as ECB president, provided a French candidate receives the powerful chief economist role, Reuters reports.
The proposal reportedly has Macron’s backing, with Pablo Hernández de Cos seen as Knot’s main rival.
Market angle: Germany is expected to resist the deal, setting up a major battle over the ECB’s future policy direction.
Alpha Talon Investment Research Limited. retweeted
Q2 2026 was $GOOGL first negative free cash flow quarter in history as a publicly traded company.
Insane.
Alpha Talon Investment Research Limited. retweeted
Added 74 new stock write-ups (pt 1):
@HugoNavarroPer2 (NPL company overviews) - $ACR.OL, $HOFI.ST, $INTRUM.ST, $KRU.WA, $B2I.OL, $PRAA, $ECPG, $BST.WA, $DOV.MI
@CoffeeStocksGuy - $AVCT.L
@AlphaSeeker84 - $BLK, $C
@AlphaTalon2025 - $ARCC
@akramsrazor - $NOW (update)
Alpha Talon Investment Research Limited. retweeted
Added 63 new stock write-ups to the site (pt 3):
@topsecretstocks - $QS, $MP
@jpinsights - $IQE.L (watchlist)
@RandianCapital - $FRMI
@michaelsikand - $ERII
@babyfolio - $AIRJ (pass)
@aalim_rehman - $SPWL.KA (pass)
@AlphaTalon2025 (updates) - $GRCE, $SNDK, $ABVX
After weeks of research and month of primary research, our deepest report yet is finally live.
We cover:
•What a Business Development Company (BDC) actually is
• Why private credit is replacing traditional banks
• A complete breakdown of $ARCC 's $29.5B investment portfolio
• Ivy Hill Asset Management and its hidden fee-income engine
• Financial analysis, NAV, NII, leverage and dividend sustainability
• Performance through the Global Financial Crisis, COVID-19 and every major credit cycle
• Industry outlook and structural growth of private credit
• Peer comparison against $BXSL , $MAIN , $OBDC , $FSK and $CSWC
• Risk analysis and downside scenarios
• Five-year valuation, price target and expected total returns
Our conclusion remains straightforward: $ARCC isn't simply a high-yield stock. It's an institutional-quality private credit platform with one of the strongest underwriting records, most diversified portfolios, and most durable dividend profiles in the public markets.
For investors seeking sustainable double-digit income with long-term capital appreciation, we believe ARCC deserves consideration as a core portfolio holding.
Read the full research here:
open.substack.com/pub/alphat…
82
Absolutely ridiculous!
SpaceX's market cap crossed above $3 trillion today in after hours trading.
That's higher than the market cap of Amazon ($2.65 trillion) & Microsoft ($2.97 trillion).
Microsoft Sales: $318 billion
Microsoft Net Income: $125 billion
Amazon Sales: $743 billion
Amazon Net Income: $91 billion
SpaceX Sales: $19 billion
SpaceX Net Income: -$9 billion
Now $ABVX is no longer investable at all, the high dose of Obe caused 2 x pregnancy, none with placebo or 25 mg!
@Taintslapp12283
Alpha Talon Investment Research Limited. retweeted
Today @Citadel has come out and covered the shift toward cheaper AI models
This is squarely in line with my thesis
xitter.cf/Moshaikh/status/206471…
The most basic way AI could blow up imo. I'm not saying it does but this is the most obvious way I can see it happening
- Per seat subscriptions are massively subsidized. The flat fee was priced way below what heavy usage actually costs
- For real business use you have to move to the API anyway. Data protections, work integrations and compliance officer approval
- On the API you pay metered rates, and businesses are burning credits way faster than the per seat pricing ever led them to expect
- This is everywhere right now. Internally for us, Codex users, Uber torching its entire 2026 AI budget in 4 months, the Microsoft comments. Just go try an API
I shared more on this here: xitter.cf/Shaughnessy119/status/…
- And I don't think most businesses have the money to keep paying increasing API rates without a real change to how they operate (caps needed)
- Because they have a cheap alternative. They can reach open source models through any aggregator (OpenRouter, Venice, Baseten, Together) and still get strong privacy. Venice private data centers, or E2EE/TEE serving GLM 5.1.
More on open source inference provider raises here: xitter.cf/Shaughnessy119/status/…
- And the discount is enormous. DeepSeek V4 codes within a hair of Opus on SWE bench at roughly 1/30th the price, and the cheapest open models run closer to 1/100th
- Chinese labs open source frontier grade models. The model is the single biggest cost an inference provider has, and they get it for free
- This idea dies if China goes closed source. That is actually bullish web2 AI labs, because if everyone is closed you pay up for the best intelligence. China goes closed source if they are tired of giving away an asset and they want the revenue and data flow to train new models
- Is this showing up in web2 AI lab revenue yet? No. Revenue is off the charts. Anthropic went from 9B to 47B run rate in five months
- So go forward, what happens?
- I think revenue slowly starts leaking to the open source inference providers (see Venice usage, OpenRouter's $113M raise, Baseten is raising at $11B or triple its valuation in three months, on revenue that went from $200M to $600M annualized in a single quarter)
- It doesnt move overnight, but it caps the labs ability to raise prices, and margins are already deeply negative. OpenAI is reportedly running near negative 122%
- With margins that bad there is no cash flow, so the labs are fully dependent on outside capital to buy GPUs, train models, and keep subsidizing usage (I.e. see Google tapping $80b equity sale, granted 30b for employee RSU taxes. Clearly they think Equity is overvalued or you wouldn't sell it)
- The break comes when that capital stops. Pricing is capped so margins cant improve, and the moment investors lose conviction on payback, the whole flow reverses
- Why would they lose conviction on payback? Back to the start - the inability to improve margins or get businesses to pay more
- This is also limiting, if we start making new drugs with AI or create entirely new businesses, you better believe people will pay up to the max for AI usage
So $ABVX went from ~$180 after hours to ~$69 on the slide below, which people have (misguidedly IMO) interpreted as a cancer risk in the high dose arm.
This looks very much like noise - 2 cases (one each, a rate of 0.5%) of the 2 most common cancers in the world (breast and prostate). Zero cases in the low dose arm. NMSC is a throwaway side note and almost always age related - as they noted they *were* in this case. The only thing to adjudicate is the prostate and breast cases.
They also noted ZERO cases in the long term extension study from phase 2, which consisted of well over 100 patients and has had some patients on drug for 7+ years, ALL of them on drug for >2 years.
2 cases (again, 1 each) of the 2 most common cancers in the world among all those patients (P2+P3) over all those years. This is noise.
Let's say you *don't* think this is noise for the high dose...
Well, then it's a good thing that the low dose showed zero malignancy signal vs placebo and *still* came in with efficacy vastly above the market's expectations (39% delta vs 40% for the high dose).
The low dose with 39.3% delta and no cancer signal is right there with the (previously) highest reported efficacy drug, Rinvoq...Except, Rinvoq has a black box warning that has *5* bullet points:
-Serious infections "leading to hospitalization or death"
-Higher rate of all cause mortality "including sudden cardiovascular death"
-MALIGNANCIES "including lymphomas and lung cancers"
-Higher rate of MACE (including heart attacks and strokes)
-Thrombosis (including pulmonary embolism)
So, let's say you do think this gets a black box warning for malignancy risk (even despite all the notes above, and the fact that the low dose had zero cases of non-NMSC malignancy and was balanced with placebo on NMSC)...
...then you are looking at a WORST CASE scenario of 1 bullet on a black box warning versus *5* for Rinvoq (and the other JAK inhibitors).
The 2nd highest clinical remission delta for a non black box warning drug ever is...Entyvio at 26%....
So you have 2 JAKi with 5 black box warning "points" and remission deltas of 39.8% (Rinvoq) and 30% (Xeljanz).
Again, WORST case, $ABVX gets 1 black box warning "point" despite all the evidence that this is just noise and had 39.3% and 40.3% remission delta.
Want something without a black box? You're looking at 20-26% delta. And again, that's *if* this is actually something the FDA doesn't think is noise. You've got the 25mg dose with literally zero signal versus placebo and 7+year P2 dataset saying zero signal as well with many of those patients having been on higher than 25 mg doses.
At $70 AH this is a $6B company? Absurd from my perspective. At worst this is the most efficacious drug in the industry with a black box warning 1/5th as bad as the JAKis that do big numbers in this disease at WORST.
$ABVX ... MARC De GARIDEL did it again ... he waited for data ... and stock crashed 50% (for the wrong reasons) ... this time he just had bad luck I guess
Best in class drug! And everyone says cancer not drug related (no signs in 7 year of phase 2b) ... go figure out and long!
Alpha Talon Investment Research Limited. retweeted
This is the bluest possible blue sky scenario. FUCKING SHAKING. THANK YOU MARC.
Alpha Talon Investment Research Limited. retweeted
$ABVX Congratulations to Abivax! All of our shareholders are becoming future patients.
It’s called stress induced IBS.
We are winning like never before!
Thank you for your attention to this matter.
- MDG
Alpha Talon Investment Research Limited. retweeted
As is the size of SoftBank’s balance sheet since 2000.
AI revolution is '50x bigger' than the dotcom boom: SoftBank's Masayoshi Son to CNBC cnbc.com/2026/06/01/softbank…
















































